L-697661
| Code | Size | Price |
|---|
| TAR-T27770-5mg | 5mg | £1,091.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27770-50mg | 50mg | £2,143.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27770-100mg | 100mg | £2,801.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
L-697661, a reverse transcriptase inhibitor, is used potentially for the treatment of HIV infection.
CAS:
135525-78-9
Formula:
C16H15Cl2N3O2
Molecular Weight:
352.22
Purity:
0.98
SMILES:
CCc1cc(NCc2nc3c(Cl)ccc(Cl)c3o2)c(=O)[nH]c1C
References
1. Perrin L, Rakik A, Yerly S, Baumberger C, Kinloch-de Lo?s S, Pech?re M, Hirschel B. Combined therapy with zidovudine and L-697,661 in primary HIV infection. AIDS. 1996 Sep;10(11):1233-7. PubMed PMID: 8883585.
2. Schooley RT, Campbell TB, Kuritzkes DR, Blaschke T, Stein DS, Rosandich ME, Phair J, Pottage JC, Messari F, Collier A, Kahn J. Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 1;12(4):363-70. PubMed PMID: 8673545.
3. Kilby JM, Saag MS. Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine. Adv Exp Med Biol. 1996;394:291-8. Review. PubMed PMID: 8815693.
4. Staszewski S, Massari FE, Kober A, G?hler R, Durr S, Anderson KW, Schneider CL, Waterbury JA, Bakshi KK, Taylor VI, et al. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. J Infect Dis. 1995 May;171(5):1159-65. PubMed PMID: 7538547.